دورية أكاديمية
أعرض في EDS

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control.

التفاصيل البيبلوغرافية
العنوان: Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control.
المؤلفون: Youssef ME; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt., Yahya G; Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Al Sharqia 44519, Egypt., Popoviciu MS; Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, Romania., Cavalu S; Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, Romania., Abd-Eldayem MA; Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Horus University, New Damietta 34518, Egypt., Saber S; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 Mar 23; Vol. 24 (7). Date of Electronic Publication: 2023 Mar 23.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Diabetes Mellitus, Type 2*/epidemiology , Sodium-Glucose Transporter 2 Inhibitors*/pharmacology , Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use, Humans ; Acetylcholinesterase ; Glycemic Control ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use
مستخلص: The number of diabetic patients has risen dramatically in recent decades, owing mostly to the rising incidence of type 2 diabetes mellitus (T2DM). Several oral antidiabetic medications are used for the treatment of T2DM including, α-glucosidases inhibitors, biguanides, sulfonylureas, meglitinides, GLP-1 receptor agonists, PPAR-γ agonists, DDP4 inhibitors, and SGLT2 inhibitors. In this review we focus on the possible effects of SGLT2 inhibitors on different body systems. Beyond the diabetic state, SGLT2 inhibitors have revealed a demonstrable ability to ameliorate cardiac remodeling, enhance myocardial function, and lower heart failure mortality. Additionally, SGLT2 inhibitors can modify adipocytes and their production of cytokines, such as adipokines and adiponectin, which enhances insulin sensitivity and delays diabetes onset. On the other hand, SGLT2 inhibitors have been linked to decreased total hip bone mineral deposition and increased hip bone resorption in T2DM patients. More data are needed to evaluate the role of SGLT2 inhibitors on cancer. Finally, the effects of SGLT2 inhibitors on neuroprotection appear to be both direct and indirect, according to scientific investigations utilizing various experimental models. SGLT2 inhibitors improve vascular tone, elasticity, and contractility by reducing oxidative stress, inflammation, insulin signaling pathways, and endothelial cell proliferation. They also improve brain function, synaptic plasticity, acetylcholinesterase activity, and reduce amyloid plaque formation, as well as regulation of the mTOR pathway in the brain, which reduces brain damage and cognitive decline.
References: Cell Death Dis. 2019 May 29;10(6):420. (PMID: 31142735)
World J Diabetes. 2019 Apr 15;10(4):249-259. (PMID: 31040901)
Drugs. 2004;64(12):1339-58. (PMID: 15200348)
Rev Endocr Metab Disord. 2021 Dec;22(4):1121-1136. (PMID: 34272645)
Eur Radiol Exp. 2019 Apr 11;3(1):17. (PMID: 30972589)
Front Nutr. 2021 Feb 17;8:625331. (PMID: 33681276)
Molecules. 2020 Jan 23;25(3):. (PMID: 31979355)
Neurochem Int. 2021 Nov;150:105158. (PMID: 34391818)
Physiology (Bethesda). 2016 May;31(3):233-45. (PMID: 27053737)
Saudi Pharm J. 2022 Jun;30(6):863-873. (PMID: 35812142)
Front Endocrinol (Lausanne). 2019 Apr 26;10:260. (PMID: 31080438)
Front Pharmacol. 2019 Jan 08;9:1517. (PMID: 30670968)
Obesity (Silver Spring). 2014 Aug;22(8):1821-9. (PMID: 24753506)
J Biol Chem. 1998 Mar 27;273(13):7501-6. (PMID: 9516450)
Int J Mol Sci. 2019 Mar 09;20(5):. (PMID: 30857271)
Int J Biochem Cell Biol. 2021 Aug;137:106031. (PMID: 34175459)
Sci Rep. 2018 Jun 11;8(1):8805. (PMID: 29891844)
Nat Rev Drug Discov. 2019 Jul;18(7):527-551. (PMID: 30867601)
Trends Pharmacol Sci. 2015 Jul;36(7):461-70. (PMID: 26022934)
Br J Cancer. 2023 Apr;128(8):1541-1547. (PMID: 36765176)
Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1428-1440. (PMID: 34156119)
Diabetes Obes Metab. 2019 Apr;21 Suppl 2:9-18. (PMID: 31081592)
Diabetes. 2015 Dec;64(12):3984-6. (PMID: 26604172)
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Dec;1865(12):158813. (PMID: 32920139)
Endocr Rev. 2021 Mar 15;42(2):101-132. (PMID: 33320179)
Diabetes Obes Metab. 2014 Feb;16(2):159-69. (PMID: 23906445)
Cardiovasc Res. 2019 Sep 1;115(11):1646-1658. (PMID: 30715251)
J Neurochem. 2018 Oct;147(2):190-203. (PMID: 30022488)
Front Pharmacol. 2021 Aug 16;12:719984. (PMID: 34489707)
J Cardiol. 2018 May;71(5):471-476. (PMID: 29415819)
Biochim Biophys Acta. 2007 Nov;1768(11):2690-7. (PMID: 17692818)
Diabetes. 2014 Jul;63(7):2196-202. (PMID: 24962916)
Pharmacol Res. 2020 Nov;161:105108. (PMID: 32738493)
Diabetologia. 2019 Jul;62(7):1154-1166. (PMID: 31001673)
Biomed Res Int. 2022 Dec 24;2022:3959845. (PMID: 36593773)
ACS Chem Neurosci. 2021 Feb 17;12(4):689-703. (PMID: 33543924)
Front Neurosci. 2021 Aug 11;15:708547. (PMID: 34489627)
Curr Cardiol Rev. 2010 Nov;6(4):337-42. (PMID: 22043210)
Int J Mol Sci. 2019 Sep 30;20(19):. (PMID: 31575077)
Animals (Basel). 2022 Jul 31;12(15):. (PMID: 35953935)
Biomed Pharmacother. 2022 Jan;145:112455. (PMID: 34844106)
Curr Osteoporos Rep. 2022 Dec;20(6):379-388. (PMID: 36214991)
Sci Rep. 2017 Jan 27;7:41166. (PMID: 28128227)
Free Radic Biol Med. 2017 Mar;104:298-310. (PMID: 28132924)
Cardiovasc Drugs Ther. 2018 Apr;32(2):213-222. (PMID: 29679303)
Pharmaceuticals (Basel). 2020 Nov 11;13(11):. (PMID: 33187206)
JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. (PMID: 32613148)
PLoS One. 2020 Apr 28;15(4):e0232283. (PMID: 32343721)
Int J Oncol. 2020 Nov;57(5):1223-1233. (PMID: 32901837)
Metabolism. 2018 Oct;87:48-55. (PMID: 30253864)
Am J Physiol. 1999 Jul;277(1):E1-10. (PMID: 10409121)
Pharmacol Rep. 2017 Dec;69(6):1328-1340. (PMID: 29132091)
Curr Top Med Chem. 2019;19(20):1818-1849. (PMID: 31456521)
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7. (PMID: 12829793)
Am J Med. 2004 Mar 8;116 Suppl 5A:23S-29S. (PMID: 15019860)
Drugs. 2001;61(11):1625-60. (PMID: 11577798)
JBMR Plus. 2019 Nov 04;3(11):e10242. (PMID: 31768494)
Alzheimers Res Ther. 2015 Jun 10;7(1):46. (PMID: 26060511)
Oncol Lett. 2022 Sep 22;24(5):401. (PMID: 36276495)
J Bone Miner Res. 2017 Mar;32(3):449-460. (PMID: 27664946)
J Am Soc Nephrol. 2006 May;17(5):1305-15. (PMID: 16597685)
Diabetol Metab Syndr. 2017 Sep 25;9:75. (PMID: 29021829)
Front Endocrinol (Lausanne). 2022 Feb 21;13:846903. (PMID: 35265043)
Nutrients. 2020 Jul 15;12(7):. (PMID: 32679784)
Ther Adv Chronic Dis. 2022 Apr 11;13:20406223221086996. (PMID: 35432846)
Mol Cell Endocrinol. 2019 Aug 20;494:110487. (PMID: 31195080)
Diabetes Obes Metab. 2019 Aug;21(8):1871-1877. (PMID: 30972917)
Hypertension. 1988 Jun;11(6 Pt 2):724-38. (PMID: 3292417)
BMC Neurol. 2018 Jun 7;18(1):81. (PMID: 29879920)
Int J Mol Sci. 2019 Jul 04;20(13):. (PMID: 31277431)
Front Endocrinol (Lausanne). 2020 Mar 24;11:122. (PMID: 32265831)
J Hypertens. 2004 Dec;22(12):2253-61. (PMID: 15614015)
Medicina (Kaunas). 2021 Dec 11;57(12):. (PMID: 34946298)
Endocrinology. 2021 Aug 1;162(8):. (PMID: 33857309)
Diab Vasc Dis Res. 2015 Mar;12(2):78-89. (PMID: 25616707)
Physiol Rev. 2011 Apr;91(2):733-94. (PMID: 21527736)
Diabetes Ther. 2020 Jun;11(6):1347-1367. (PMID: 32372382)
Front Endocrinol (Lausanne). 2018 Aug 31;9:496. (PMID: 30233495)
J Neurochem. 2006 Jul;98(1):279-88. (PMID: 16805814)
J Diabetes Investig. 2020 Jul;11(4):770-782. (PMID: 32196987)
Arch Med Sci. 2013 Oct 31;9(5):936-43. (PMID: 24273582)
J Clin Endocrinol Metab. 2011 Jul;96(7):E1100-7. (PMID: 21565787)
Diabetologia. 2017 Oct;60(10):1862-1872. (PMID: 28725912)
BMJ. 2012 Mar 12;344:e1369. (PMID: 22411919)
Sci Transl Med. 2018 Nov 14;10(467):. (PMID: 30429355)
Life Sci. 2021 Dec 1;286:120070. (PMID: 34688695)
Neural Regen Res. 2022 Feb;17(2):292-299. (PMID: 34269190)
Physiology (Bethesda). 2017 Nov;32(6):435-443. (PMID: 29021363)
Obes Rev. 2010 Jan;11(1):11-8. (PMID: 19656312)
Cancer Metab. 2019 Dec 11;7:10. (PMID: 31867105)
Front Physiol. 2021 Feb 25;11:588664. (PMID: 33716756)
Biochem Biophys Res Commun. 2012 Jun 8;422(3):358-62. (PMID: 22554511)
Bone. 2019 Jan;118:89-98. (PMID: 29366839)
Curr Diab Rep. 2018 Oct 18;18(12):131. (PMID: 30338401)
Diabetologia. 2018 Oct;61(10):2098-2107. (PMID: 30132034)
Pharmacol Res. 2017 Apr;118:71-81. (PMID: 27389050)
J Clin Endocrinol Metab. 2016 Jan;101(1):44-51. (PMID: 26580234)
Diabetes Metab. 2018 Dec;44(6):457-464. (PMID: 30266577)
Cell Biol Int. 2018 Apr;42(4):384-392. (PMID: 29205673)
Pharmacol Res. 2022 Feb;176:106062. (PMID: 35017046)
Acta Physiol (Oxf). 2018 Apr;222(4):e13050. (PMID: 29424089)
Front Public Health. 2021 Jun 07;9:668368. (PMID: 34164370)
Pflugers Arch. 2020 Sep;472(9):1177-1206. (PMID: 32767111)
Pharmacol Ther. 2007 Mar;113(3):546-93. (PMID: 17306374)
Diabetes Obes Metab. 2012 Feb;14(2):101-11. (PMID: 21752172)
Chronic Dis Transl Med. 2020 Aug 15;6(4):239-245. (PMID: 33336169)
N Am J Med Sci. 2014 Mar;6(3):107-13. (PMID: 24741548)
Diabetologia. 2017 Sep;60(9):1566-1576. (PMID: 28776081)
Biomed Pharmacother. 2022 Mar;147:112628. (PMID: 35032769)
Curr Drug Targets. 2012 Jun;13(7):994-1003. (PMID: 22420308)
Diabetologia. 2018 Oct;61(10):2118-2125. (PMID: 30132031)
Curr Pharm Des. 2015;21(25):3606-20. (PMID: 26166608)
Mol Metab. 2016 Aug 26;5(10):1048-1056. (PMID: 27689018)
J Neurol. 2009 Aug;256(8):1288-95. (PMID: 19353221)
Biomed Pharmacother. 2022 Sep;153:113409. (PMID: 36076534)
Biotechnol Appl Biochem. 2016 Jan-Feb;63(1):145-50. (PMID: 25402624)
Front Endocrinol (Lausanne). 2021 Oct 21;12:738848. (PMID: 34745006)
Annu Rev Public Health. 2015 Mar 18;36:441-62. (PMID: 25581145)
J Bone Miner Res. 2014 Apr;29(4):787-95. (PMID: 24123088)
Biochem Soc Trans. 2015 Oct;43(5):901-7. (PMID: 26517901)
Arch Biochem Biophys. 2014 Nov 1;561:154-8. (PMID: 24997362)
Indian J Psychol Med. 2020 Jan 06;42(1):102-103. (PMID: 31997873)
Cell. 1995 Dec 1;83(5):803-12. (PMID: 8521497)
Biochem Biophys Res Commun. 2017 Nov 4;493(1):40-45. (PMID: 28928093)
Br J Nutr. 2003 Jan;89(1):3-9. (PMID: 12568659)
Expert Opin Biol Ther. 2019 Sep;19(9):937-948. (PMID: 31079501)
Clin Obes. 2018 Apr;8(2):131-139. (PMID: 29334695)
J Clin Pharmacol. 2021 Feb;61(2):187-192. (PMID: 32827151)
Adipocyte. 2018;7(4):277-284. (PMID: 30161013)
Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. (PMID: 24348059)
Annu Rev Med. 2015;66:255-70. (PMID: 25341005)
Bone. 2016 Jan;82:101-7. (PMID: 26211996)
Diseases. 2020 May 11;8(2):. (PMID: 32403420)
Br J Pharmacol. 2012 Dec;167(7):1520-32. (PMID: 22817481)
Int J Clin Pract. 2017 May;71(5):. (PMID: 28440009)
J Inherit Metab Dis. 2022 Jul;45(4):759-768. (PMID: 35506446)
Clin Sci (Lond). 2021 Jul 30;135(14):1669-1687. (PMID: 34283205)
Mol Metab. 2022 Oct;64:101553. (PMID: 35863636)
Life (Basel). 2022 May 27;12(6):. (PMID: 35743834)
Biomed Pharmacother. 2022 Nov;155:113675. (PMID: 36115110)
Biomedicines. 2021 Mar 30;9(4):. (PMID: 33808404)
Int J Mol Sci. 2021 Feb 07;22(4):. (PMID: 33562380)
Life Sci. 2021 Feb 15;267:118974. (PMID: 33385407)
Int J Mol Sci. 2021 Aug 16;22(16):. (PMID: 34445519)
J Cell Physiol. 2019 May;234(5):5674-5682. (PMID: 30417374)
J Cell Physiol. 2017 Jan;232(1):61-8. (PMID: 27279601)
Adv Ther. 2017 Jul;34(7):1707-1726. (PMID: 28631216)
Endocrinol Metab Clin North Am. 1989 Mar;18(1):163-83. (PMID: 2645125)
Endocr Rev. 2002 Apr;23(2):201-29. (PMID: 11943743)
Signal Transduct Target Ther. 2017;2:. (PMID: 29158945)
Int J Endocrinol. 2018 Nov 14;2018:9128754. (PMID: 30595693)
Diabetologia. 2018 Oct;61(10):2079-2086. (PMID: 30132033)
Diabetes Obes Metab. 2018 Mar;20(3):520-529. (PMID: 28857451)
J Osteopath Med. 2021 Feb 1;121(2):229-239. (PMID: 33567084)
Nat Rev Drug Discov. 2016 Sep;15(9):639-660. (PMID: 27256476)
JACC Basic Transl Sci. 2020 Jan 29;5(2):169-179. (PMID: 32140623)
J Cell Physiol. 2019 Aug;234(10):16987-16997. (PMID: 30825205)
Genes Nutr. 2011 Aug;6(3):285-306. (PMID: 21484167)
Cancers (Basel). 2022 Nov 25;14(23):. (PMID: 36497303)
J Cell Mol Med. 2021 Aug;25(16):7642-7659. (PMID: 34169635)
Pharmacol Res. 2022 Jul;181:106261. (PMID: 35588918)
PLoS One. 2010 Apr 20;5(4):e10241. (PMID: 20421923)
Circulation. 2004 Jun 29;109(25):3244-55. (PMID: 15198946)
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4111-9. (PMID: 26170283)
Life Sci. 2020 Dec 1;262:118401. (PMID: 32926928)
Cell Commun Signal. 2020 Jun 3;18(1):83. (PMID: 32493394)
Nat Rev Endocrinol. 2014 Jan;10(1):24-36. (PMID: 24146030)
Toxicol Appl Pharmacol. 2017 Oct 15;333:43-50. (PMID: 28807765)
J Neurosci. 2022 Apr 20;42(16):3426-3444. (PMID: 35232764)
BMC Vet Res. 2005 Nov 02;1:8. (PMID: 16266437)
فهرسة مساهمة: Keywords: SGLT2 inhibitors; bone minerals; cancer; cardiorenal effects; cardiovascular effects; cognitive effects; metabolism
المشرفين على المادة: EC 3.1.1.7 (Acetylcholinesterase)
0 (Hypoglycemic Agents)
0 (Sodium-Glucose Transporter 2 Inhibitors)
0 (SLC5A2 protein, human)
تواريخ الأحداث: Date Created: 20230413 Date Completed: 20230415 Latest Revision: 20230415
رمز التحديث: 20230415
مُعرف محوري في PubMed: PMC10094124
DOI: 10.3390/ijms24076039
PMID: 37047011
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms24076039